Adverse effects observed in trials include: Nausea and vomiting particularly during dose escalation Diarrhoea or constipation Decreased appetite Injection site reactions Fatigue and dizziness Gallbladder-related events (including gallstones), consistent with effects observed with other GLP-1based therapies [9] Rare cases of pancreatitis , a risk associated with the GLP-1 receptor agonist class [10] [3] Because retatrutide is not licensed in the UK, the MHRA has not issued specific prescribing or dosing guidance for this compound
The classification criteria then include a history of chronic widespread pain and the presence of 11 or more out of 18 tender points (TPs)
This page is for informational and educational purposes only and makes no claims of therapeutic benefit
Avoid strenuous physical activity for 24 hours after your injection to prevent additional swelling, bruising, or tenderness
This article explores the evidence, clinical considerations, and practical guidance for patients and healthcare professionals
We do not look at personal stories as isolated events